| Cat. No. : |
CTSK-680H |
| Description : |
The protein encoded by this gene is a lysosomal cysteine proteinase involved in bone remodeling and resorption. This protein, which is a member of the peptidase C1 protein family, is predominantly expressed in osteoclasts. However, the encoded protein is also expressed in a significant fraction of human breast cancers, where it could contribute to tumor invasiveness. Mutations in this gene are the cause of pycnodysostosis, an autosomal recessive disease characterized by osteosclerosis and short stature. This gene may be subject to RNA editing. |
| Source : |
E. coli |
| Molecular Mass : |
Active cathepsin obtained after removal of the propeptide has a molecular weight of about 24 kDa. |
| Form : |
The proenzyme is dissolved in 500 mM NaCl, 25 mM TrisHCl, pH 8.0. |
| Purity : |
Recombinant procathepsin K appears as a major protein band of about 35 kDa in SDS-PAGE (> 95 % of total protein) and Western Blotting. |
| Specific activity : |
The specific activity of activated cathepsin K is > 1 U/mg. One U is the activity that hydrolyses 1 µmole substrate BOC-Phe-Arg-7-amido-4-methylcoumarin per min at 37oC in 2.5 mM EDTA, 5 mM DTT, 50 mM MES, pH 5.5. |
| Inhibitors : |
Cathepsin K is inhibited by leupeptin (IC50: 70 nM), E-64 (IC50: 5 nM), and cystatin. |
| Stability andstorage : |
Procathepsin K is stable until the expiry date given on the label if stored at -80°C. Repeated freezing and thawing must be avoided. After activation the enzyme is rather unstable. If the activated enzyme is not used immediately, it is recommended to add MMTS (1 mM final concentration). For activity measurements L-cysteine must then be added to restore the active conformation of the enzyme. |
| Applications : |
Characterization of cathepsin K structure and function; Screening of inhibitors for cathepsin K; Drug target for diseases characterized by excessive bone reabsorption, such as osteoporosis. |
| OfficialSymbol : |
CTSK |
